Skip To Main Content
Katell Bidet Huang on Muck Rack

Katell Bidet Huang

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katell Bidet

Contact Katell Bidet, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial

|
By Christian Ottensmeier, Jean-Pierre Delord, Ana Ines Lalanne, Anne-Laure Le Gac, Katell Bidet Huang, Jules Deforges, Éric Quéméneur, Sylvain Robin, Emmanuelle Dochy, Alessandro Riva, Naoko Yamagata, Per Ludvik Brattås, Mariana Martinez, Mariana Martínez Verified, Oliver Baker, Terry Jones, Andrew Schache, Eliane Piaggio, Kaidre Bendjama, Olivier Lantz, Christophe Le Tourneau, Camille Jamet, Benoît Grellier, Maud Brandely, Bérangère Bastien, Annette Tavernaro, Gisèle Lacoste, Valérie Schoettel, Clémentine Spring-Giusti, Nathalie Silvestre, Jean-Baptiste Marchand, Maurizio Ceppi, Kazuhide Onoguchi, Yoshiko Yamashita, Hugues Fontenelle
| Nature Verified
Abstract In approximately one third of patients, resected head and neck squamous cell carcinoma will recur. We postulated that the induction of tumor neoantigen-specific T cell responses could prevent relapse. To this end, we developed TG4050, an individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted tumor neoantigens delivered by a Modified Vaccinia Ankara viral vector.
Open in Who Shared Issue with article?

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine

|
By Catarina Pinto, Romana Bischl, Lea Knezevic, Sarah Schmidt, Peter Steinberger, Henning Lauterbach, Josipa Raguz, Sarah Ahmadi-Erber, Katell Bidet Huang, Klaus K. Orlinger
| Nature Verified
Abstract KRAS mutations are frequent oncogenic drivers in several indications, yet limited targeted therapy options are available. Here we engineered our clinically validated artARENA platform to develop an “off-the-shelf” shared neoantigen vaccine, capable of triggering potent CD8+ T-cell responses against the five most prevalent KRAS mutations (G12D, G12V, G12C, G12R, and G13D).
Open in Who Shared Issue with article?
See all 2 articles